Novo Nordisk goes long, extends debt curve at minimal cost
14 Nov 2025Novo Nordisk returned to the market this week with a €4bn multi-part trade primarily aimed at extending its debt profile amid a period of brief respite from the decline in its share price, which has been on a downward spiral
